All In Biotech

Drug Trial Radar · NCT03838848

KN046 in Patients With Advanced Non-small Cell Lung Cancer

A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

120

Actual

Start

May 5, 2019

Primary completion

Jul 30, 2022

Study completion Jul 30, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.

Conditions

  • Stage IV Non-small Cell Lung Cancer

Interventions

  • KN046Drug

    3mg/kg, Q2W, intravenous injection (IV)

  • KN046Drug

    5mg/kg, Q2W, intravenous injection (IV)

  • KN046Drug

    5mg/kg, Q3W, intravenous injection (IV)

  • CarboplatinDrug

    AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.

  • PemetrexedDrug

    500 mg/m2, Q3W, intravenous injection (IV)

  • NingetinibDrug

    Oral, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 2 years
  2. DORTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.